The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 Summer Meeting | Could ctDNA replace routine tissue testing for genotyping NSCLC?
Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHSFT/BTOG Steering Committee, UK, discusses the challenges faced with circulating tumor (ct)DNA implementation and whether it could replace tissue testing as the standard for genotyping non-small cell lung cancer (NSCLC). Currently, the most prominent challenge faced with the implementation of ctDNA for routine genotyping of NSCLC is a lack of funding. Additionally, not every patient sheds ctDNA, resulting in missed tier one drivers. This interview took place at the BTOG 2022 Summer Meeting congress in London.
